Advisory Board covers all angles

In the latest article about the apparent end of the semaglutide shortage, the Advisory Board (which targets health care C-level folks), quoted APC about our concern that the demand for FDA-approved semaglutide injections is about to skyrocket in "The GLP-1 shortage is over. What’s next for compounders?". That concern is echoed by other organizations, and it calls into question the agency's decision.

The article also, interestingly, dove into how some compounders might still be able to dispense semaglutide injections, and how various companies, e.g., Hims & Hers, are planning to operate in the near future.